Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:INFI
- CUSIP: 45665G30
- Web: www.infi.com
Capitalization:- Market Cap: $70.62 million
- Outstanding Shares: 50,443,000
Average Prices:- 50 Day Moving Avg: $1.66
- 200 Day Moving Avg: $2.12
- 52 Week Range: $0.84 - $3.84
P/E:- Trailing P/E Ratio: 700.00
- Foreward P/E Ratio: -0.99
- P/E Growth: -0.02
Sales & Book Value:- Annual Revenue: $9.47 million
- Price / Sales: 7.46
- Book Value: $1.46 per share
- Price / Book: 0.96
Profitability:- EBIDTA: ($88,200,000.00)
- Return on Equity: -77.26%
- Return on Assets: -51.26%
Debt:- Debt-to-Equity Ratio: 0.26%
- Current Ratio: 7.60%
- Quick Ratio: 7.60%
Misc:- Average Volume: 499,279 shs.
- Beta: 2.63
- Short Ratio: 2.61
Frequently Asked Questions for Infinity Pharmaceuticals (NASDAQ:INFI)
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its earnings results on Tuesday, May, 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $19.60 million. The firm's revenue was down 99.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.82) EPS. View Infinity Pharmaceuticals' Earnings History.
Where is Infinity Pharmaceuticals' stock going? Where will Infinity Pharmaceuticals' stock price be in 2017?
4 analysts have issued 1-year price targets for Infinity Pharmaceuticals' stock. Their forecasts range from $1.00 to $1.00. On average, they expect Infinity Pharmaceuticals' share price to reach $1.00 in the next year. View Analyst Ratings for Infinity Pharmaceuticals.
Are investors shorting Infinity Pharmaceuticals?
Infinity Pharmaceuticals saw a decrease in short interest in June. As of June 30th, there was short interest totalling 1,512,502 shares, a decrease of 55.8% from the June 15th total of 3,420,737 shares. Based on an average trading volume of 993,299 shares, the short-interest ratio is presently 1.5 days. Currently, 3.1% of the shares of the company are sold short.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include OncoMed Pharmaceuticals (OMED), Matinas BioPharma Holdings (MTNB), Pluristem Therapeutics (PSTI), Oramed Pharmaceuticals (ORMP), Vernalis plc (VER), CTI BioPharma Corp. (CTIC), Brainstorm Cell Therapeutics (BCLI), ArQule (ARQL), CytRx Corporation (CYTR), GTx (GTXI), Tissue Regenix Group PLC (TRX), Eiger BioPharmaceuticals (EIGR), aTyr Pharma (LIFE), Navidea Biopharmaceuticals (NAVB), Galectin Therapeutics (GALT), Silence Therapeutics plc (SLN), Abzena PLC (ABZA) and Palatin Technologies (PTN).
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer
- Lawrence E. Bloch M.D. J.D., President, Principal Financial Officer, Principal Accounting Officer
- William C. Bertrand Jr., J.D., Executive Vice President, General Counsel
- Melissa Hackel, Vice President - Finance
- Joseph Pearlberg M.D. Ph.D., Vice President - Clinical Development
- Norman C. Selby, Lead Outside Independent Director
- Jose Baselga M.D., Ph.D., Independent Director
- Jeffrey Berkowitz J.D., Independent Director
- Anthony B. Evnin Ph.D., Independent Director
- Michael G. Kauffman M.D., Ph.D., Independent Director
How do I buy Infinity Pharmaceuticals stock?
Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $1.40.
MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)Earnings History by Quarter for Infinity Pharmaceuticals (NASDAQ INFI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($0.22) | ($0.21) | $19.60 million | $0.01 million | View | Listen |  |
| 3/14/2017 | Q4 2016 | ($0.57) | ($0.46) | $2.33 million | | View | N/A | |
| 11/9/2016 | Q316 | ($0.84) | ($0.39) | $6.23 million | | View | Listen | |
| 8/9/2016 | Q216 | ($0.89) | $1.05 | $13.91 million | $9.47 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.82) | ($0.82) | $8.80 million | $9.26 million | View | Listen | |
| 2/23/2016 | Q415 | ($0.72) | ($0.80) | $18.26 million | $9.10 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.76) | $0.84 | $24.85 million | $90.70 million | View | N/A | |
| 8/6/2015 | Q215 | ($1.00) | ($0.78) | $5.83 million | $4.90 million | View | N/A | |
| 5/6/2015 | Q115 | ($1.69) | ($1.91) | $5.79 million | $4.40 million | View | Listen | |
| 2/24/2015 | Q414 | ($0.99) | ($0.83) | $5.61 million | $4.36 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.87) | $2.03 | $141.40 million | $160.60 million | View | Listen | |
| 8/5/2014 | Q114 | ($0.84) | ($0.78) | | | View | N/A | |
| 5/6/2014 | Q1 | ($0.80) | ($0.87) | | | View | Listen | |
| 2/25/2014 | Q413 | ($0.87) | ($0.68) | | | View | Listen | |
| 11/7/2013 | | ($0.75) | ($0.71) | | | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.62) | ($0.68) | | | View | Listen | |
| 11/6/2012 | Q312 | ($0.57) | $0.52 | $13.90 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)2017 EPS Consensus Estimate: ($0.69)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.23) | ($0.13) | ($0.18) |
| Q2 2017 | 2 | ($0.21) | ($0.12) | ($0.17) |
| Q3 2017 | 2 | ($0.21) | ($0.13) | ($0.17) |
| Q4 2017 | 2 | ($0.21) | ($0.13) | ($0.17) |
(Data provided by Zacks Investment Research)
Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Infinity Pharmaceuticals (NASDAQ:INFI)Insider Ownership Percentage: 6.81%
Institutional Ownership Percentage: 76.49%
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/17/2017 | Michael C Venuti | Director | Sell | 6,250 | $3.48 | $21,750.00 | |
| 1/3/2017 | Value Fund L P Biotechnology | Major Shareholder | Buy | 4,379 | $1.34 | $5,867.86 | |
| 12/30/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 742,401 | $1.34 | $994,817.34 | |
| 12/20/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 654,921 | $1.31 | $857,946.51 | |
| 12/13/2016 | Sujay Kango | Insider | Sell | 75,000 | $1.28 | $96,000.00 | |
| 12/12/2016 | Sujay Kango | Insider | Sell | 25,009 | $1.30 | $32,511.70 | |
| 12/2/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 201,394 | $1.19 | $239,658.86 | |
| 6/25/2015 | Adelene Q Perkins | CEO | Sell | 5,000 | $10.93 | $54,650.00 | |
| 6/15/2015 | Vito J Palombella | Insider | Sell | 4,737 | $10.97 | $51,964.89 | |
| 5/27/2015 | Adelene Q Perkins | CEO | Sell | 10,000 | $12.81 | $128,100.00 | |
| 5/14/2015 | Adelene Q Perkins | CEO | Sell | 10,000 | $12.18 | $121,800.00 | |
| 3/16/2015 | Adelene Q Perkins | CEO | Sell | 20,000 | $16.00 | $320,000.00 | |
| 1/29/2015 | Adelene Q Perkins | CEO | Sell | 20,000 | $14.83 | $296,600.00 | |
| 12/15/2014 | Vito J Palombella | Insider | Sell | 4,737 | $16.32 | $77,307.84 | |
| 11/26/2014 | Vito J Palombella | Insider | Sell | 4,736 | $15.00 | $71,040.00 | |
| 9/30/2014 | Anthony B Evnin | Director | Sell | 112,451 | $13.56 | $1,524,835.56 | |
| 9/3/2014 | Vito J Palombella | Insider | Sell | 9,472 | $15.39 | $145,774.08 | |
| 11/27/2013 | Anthony B Evnin | Director | Sell | 163,864 | $14.82 | $2,428,464.48 | |
| 9/13/2013 | Adelene Perkins | CEO | Sell | 45,000 | $20.72 | $932,400.00 | |
| 6/20/2013 | Vito J Palombella | Insider | Sell | 23,150 | $18.53 | $428,969.50 | |
| 11/26/2012 | Christopher M Lindblom | Insider | Sell | 13,885 | $25.73 | $357,261.05 | |
| 9/7/2012 | Co Beacon | Major Shareholder | Buy | 5,416,565 | $14.50 | $78,540,192.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Infinity Pharmaceuticals (NASDAQ:INFI)
Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
| Source: |
|
| Date | Headline |
|---|
 | Financial Survey: Celator Pharmaceuticals (CPXX) versus Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - July 21 at 6:06 PM |
 | Infinity Announces the Date of Its Second Quarter 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - July 21 at 3:58 PM |
| Infinity Pharmaceuticals, Inc. (INFI) Short Interest Update
www.americanbankingnews.com - July 16 at 7:23 AM |
| Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - July 8 at 11:26 PM |
| Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 7 at 12:44 PM |
 | Company Spotlight: Verastem
www.rttnews.com - July 7 at 6:29 AM |
| Zacks: Brokerages Expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to Post -$0.22 Earnings Per Share
www.americanbankingnews.com - July 6 at 10:30 AM |
| ValuEngine Upgrades Infinity Pharmaceuticals, Inc. (INFI) to Sell
www.americanbankingnews.com - June 15 at 8:50 PM |
 | Infinity to Participate in Three Upcoming Conferences - PR Newswire (press release)
www.prnewswire.com - June 15 at 6:13 AM |
 | Infinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - June 14 at 11:23 AM |
| Infinity to Participate in Three Upcoming Conferences
finance.yahoo.com - June 14 at 11:23 AM |
| Infinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 10:55 AM |
| Infinity Pharmaceuticals Inc. (INFI) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 12 at 12:34 PM |
| Infinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - June 12 at 10:24 AM |
| Infinity Pharmaceuticals Inc. (INFI) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - June 4 at 11:14 AM |
| Infinity Pharmaceuticals Inc. (INFI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 16 at 2:34 PM |
| Infinity Pharmaceuticals Inc. (INFI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 1:34 PM |
| Infinity Pharmaceuticals Inc. (INFI) Short Interest Update
www.americanbankingnews.com - May 13 at 7:20 AM |
| Q2 2017 Earnings Forecast for Infinity Pharmaceuticals Inc. (INFI) Issued By William Blair
www.americanbankingnews.com - May 12 at 9:37 AM |
 | Verastem Reports First Quarter 2017 Financial Results
www.businesswire.com - May 10 at 6:21 PM |
| Edited Transcript of INFI earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 6:21 PM |
| Infinity Provides Company Update and Reports First Quarter 2017 ... - PR Newswire (press release)
www.prnewswire.com - May 10 at 1:18 PM |
| Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
finance.yahoo.com - May 10 at 1:18 PM |
| Infinity Pharmaceuticals Inc. (INFI) Posts Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 9 at 9:22 PM |
 | Infinity reports 1Q loss
marketbeat.com - May 9 at 5:44 PM |
 | BRIEF-Infinity reports Q1 loss per share $0.21
www.reuters.com - May 9 at 5:43 PM |
| Infinity Provides Company Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 5:43 PM |
| Investor Network: Infinity Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 12:23 PM |
| Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed
finance.yahoo.com - May 9 at 12:23 PM |
| Catalent (CTLT) Shows Strength: Stock Adds 9.8% in Session
finance.yahoo.com - May 8 at 7:29 AM |
 | Verastem Boosts Oncologic Drug Portfolio, Fuels Stock Price
seekingalpha.com - May 7 at 6:18 PM |
| Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates
www.nasdaq.com - May 4 at 6:05 PM |
| Infinity Pharmaceuticals (INFI) Earning Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 3 at 10:36 AM |
| Infinity Pharmaceuticals (INFI) Earning Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 27 at 11:50 PM |
| Infinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - April 26 at 7:26 PM |
| Somewhat Positive News Coverage Very Likely to Affect Infinity Pharmaceuticals (INFI) Share Price
www.americanbankingnews.com - April 21 at 8:09 PM |
 | AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
www.zacks.com - April 21 at 10:39 AM |
| Today's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals - Yahoo Finance
finance.yahoo.com - April 20 at 6:00 PM |
| Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19% - Yahoo Finance
finance.yahoo.com - April 20 at 6:00 PM |
| ETFs with exposure to Infinity Pharmaceuticals, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 5:48 PM |
| Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?
finance.yahoo.com - April 19 at 11:25 AM |
| Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
finance.yahoo.com - April 19 at 11:25 AM |
| Infinity Pharmaceuticals (INFI) Earns Coverage Optimism Score of 0.08
www.americanbankingnews.com - April 18 at 2:54 PM |
 | Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY...
www.finanznachrichten.de - April 18 at 11:03 AM |
| Today's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals
finance.yahoo.com - April 18 at 11:03 AM |
| Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%
finance.yahoo.com - April 18 at 11:03 AM |
| Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher
finance.yahoo.com - April 17 at 10:50 AM |
| New Strong Buy Stocks for April 10th
www.zacks.com - April 10 at 11:00 AM |
| Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session
finance.yahoo.com - April 10 at 11:00 AM |
| Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
finance.yahoo.com - April 10 at 11:00 AM |
Infinity Pharmaceuticals (INFI) Chart for Sunday, July, 23, 2017
